# US 2025/0082667 A1 · Therapeutic agents for treatment of coronavirus infection

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0082667 A1
- Document ID: US20250082667A1
- Status: Published application
- Kind: A1
- Application number: 18/244,800
- Filed: 2023-09-11
- Published: 2025-03-13
- Earliest claimed: 2020-05-27
- Inventors: Xueyun Gao
- Web page: https://patentgrep.com/patent/US20250082667A1

## CPC

- A61K 33/242: Gold; Compounds thereof
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7135: Compounds containing heavy metals
- A61K 31/80: Polymers containing hetero atoms not provided for in groups A61K31/755 - A61K31/795
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/645: {Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 31/14: for RNA viruses
- C07K 5/0806: {the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A therapeutic method for treatment of coronavirus infections. The therapeutic method includes using a composition containing a gold compound effective for Rheumatoid Arthritis treatment that both generates gold-S bonds at the active pockets of the main protease of the virus and suppresses the virus induced inflammations in the body.

## Claims

### Claim 1

A method for treatment of a coronavirus infection in an animal, comprising the steps of:
providing a gold compound as an active gradient that is effective in treating Rheumatoid Arthritis in said animal wherein a gold atom forms a gold-S bond in the coronavirus' protease active pocket and the gold compound suppresses inflammations in the animal's body; and
administering said gold compound to the animal having coronavirus infection via oral intake.

### Claim 2 (depends on 1)

The method of claim 1, wherein the gold compound is AURANOFIN having molecule formula C20H34AuO9PS0.

### Claim 3 (depends on 1)

The method of claim 1, wherein the gold compound is Aurothioglucose having molecule formula C6H11AuO5S.

### Claim 4 (depends on 1)

The method of claim 1, wherein the gold compound is gold cluster complex wherein multiple gold atoms and multiple peptides or proteins or polymers form a complex molecule, and the gold atoms emit fluorescent light under excitation.

### Claim 5 (depends on 4)

The method of claim 4, wherein the gold compound is a gold cluster complex having a molecular formula Au29(SG)27 wherein SG represents a glutathione peptide (SEQ. NO. 1) that Au represents a gold atom.

### Claim 6 (depends on 5)

The method of claim 5 wherein the coronavirus infection is COVID-19 and the coronavirus is SARS-CoV-2.

### Claim 7 (depends on 1)

The method of claim 1, wherein said step of administering is through intraperitoneal-injection or intramuscular-injection or intravenous-injection method.

### Claim 8 (depends on 1)

The method of claim 1, wherein said step of administering is through nasal inhaling method.

### Claim 9 (depends on 1)

The method of claim 1, wherein said step of providing a gold compound comprises the step of reacting gold (I) or gold (III) salt with glutathione peptide (SEQ. NO. 1) solutions.

### Claim 10 (depends on 1)

The method of claim 1, wherein the sufficient amount is in the range of 1 mg/kg.bw to 20 mg/kg.bw of the animal.

### Claim 11

A method for treatment of a coronavirus infection in an animal, the coronavirus encoding a conserved papain-like main protease critical for its replication, comprising the steps of:
providing a gold cluster compound having a molecular formula Au29(SG)27 wherein SG represents glutathione peptide (SEQ. NO. 1) and Au represents gold atom, wherein said gold cluster compound functions as an active gradient that both forms gold-S bond in the active pocket of the main protease and suppresses cytokine expressions in the animal's body.
administering said gold compound to the animal having coronavirus infection via oral intake.

### Claim 12 (depends on 14)

The method of claim 14, wherein the coronavirus infection is COVID-19 and the coronavirus is SARS-CoV-2.

### Claim 13 (depends on 14)

The method of claim 14, wherein the gold cluster compound is administered to said animal in the range of 1 mg/kg.bw to 20 mg/kg.bw of the animal.

### Claim 14 (depends on 14)

The method of claim 14, wherein the gold cluster compound is administered to said animal for at least 4 days.

### Claim 15 (depends on 14)

The method of claim 14, wherein the gold cluster compound is administered to said animal through intraperitoneal-injection or intramuscular-injection or intravenous-injection method.

### Claim 16 (depends on 14)

The method of claim 14, wherein the gold cluster compound is administered to said animal through nasal inhaling method.

### Claim 17 (depends on 14)

The method of claim 14, wherein the gold cluster compound is administered to said animal through oral-intake method.

### Claim 18

A therapeutic composition for treatment of a coronavirus infection in an animal, comprising:
about 150 μl liquid solution of about 15 mg of the gold cluster complex having a molecular formula Au29(SG)27 wherein SG represents a glutathione peptide (SEQ. NO. 1) wherein the liquid solution contains 0.9% (w/w) sodium chloride.

### Claim 19

A method for making a therapeutic composition for treatment of a coronavirus infection in an animal comprising the steps of:
reacting glutathione solution with chloroauric acid solution at ambient temperature;
dialyzing said reaction solution;
filtering said dialyzed reaction solution through a molecular weight cut resin spin column;
collecting the filtered portion of molecule weight corresponding to that of Au29(SG)27; and
determining Au29(SG)27 molecule structure using electrospray ionization mass spectrometry.
